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D-ALANINE RACEMASE MUTANTS OF like masses caused by chronic inflammatory processes) or 
MYCOBACTERIA AND USES THEREFORE "tubercules" that are seen in advanced cases. Due to the 
significance of mycobacterial diseases, prevention and con- 
CROSS-REFERENCE TO RELATED trol measures, including vaccines, diagnostics and therapies 
APPLICATIONS 5 are of major importance. 
Microorganisms of the M. avium complex have achieved 
The present application claims priority from provisional prominence as major opportunistic pathogens of AIDS 
patent application Ser. No. 601341,485, filed Dee. 18,2001, patients. M. avium is naturally resistant to most firstline 
which is incorporated herein by reference. antituberculosis drugs (Inderlied et al., 1993). This threat to 
lo public health has been partially met by therapy with appro- 
STATEMENT REGARDING GOVERNMENT priate antimicrobial agents, but unfortunately drug-resistant 
RIGHTS M. avium and M. tubevculosis strains readily appear 
. 
(Chaisson et al., 1994; Espinal et al., 2000), underscoring the 
This was made with government need to develop new and more effective anti-mycobacterial 
United States Department of Agriculture, USDA Coopera- agents, 
tive State Research Service Project Grant No. NEB. 14-108. 1s Mycobactevium smegmatis is a fast-growing nonpatho- 
The Government may have certain rights in this invention. genic mycobacterial species particularly useful in studying 
basic cellular processes of relevance to pathogenic myco- 
BACKGROUND OF THE INVENTION bacteria. The D-alanine racemase gene (alrA) is involved in 
- \ 
The present invention is directed to D-alanine racemase the synthesis of D-alanine, abasic componenf of peptidogly- 
mutants of mycobacterial species, The D-alanine racemase 20 can that forms the backbone of the cell wall. Biosynthesis of 
gene (alrA) is involved in the synthesis of D-alanine, a basic the mycobacterial cell wall has received considerable atten- tion in the search for inhibitors useful for drug therapy 
component of peptidoglycan that forms the backbone of the (Chatterjee, 1997). These cell walls display a complex 
bacterial cell wall. The present invention is also directed to architecture of glycolipids and proteins linked to the 
methods of making vaccines against patho- 25 mycolyl-arabinogalactan-peptidoglycan backbone (McNeil 
genic using such alrA mutants and the and Brennan, 1991). This structure is a barrier that contrib- 
vaccines made such The Present utes to drug resistance (Trias and Benz, 1994), and many of 
invention is further directed to use of alrA mutants in its components have been found to play a major role in 
methods for screening antim~cobacterial agents that are pathogenesis (Daffe and Draper, 1998). The analysis of the 
synergistic with peptidoglycan inhibitors. Finally, the 30 M. tubevculosis genome sequence suggests that peptidogly- 
present invention is directed to methods to identify new can biosynthesis in mycobacteria follows the general path- 
pathways of D-alanine biosynthesis for use in developing way of other bacteria, including the formation of the basic 
new drugs targeting peptidoglycan biosynthesis in myco- building block D-alanyl-D-alanine (Belanger and Inamine, 
bacteria and to identify vaccines useful against pathogenic 2000; Cole et al., 1998). D-alanine racemase (Alr) catalyzes 
mycobacteria. 3s the conversion of L-alanine into D-alanine (Julius et al., 
The publications and other materials used herein to illu- 1970), and D-alanine-D-alanine ligase catalyzes the subse- 
minate the background of the invention or provide additional quent dimerization of D-alanine into the key d i ~ e ~ t i d e  
details respecting the practice, are incorporated by reference, D-alan~l-D-alanine (Neuhaus, 1962). The corresponding 
and for convenience are referenced in the following text by enzymes from both Eschevichia coli (Lambert and Neuhaus, 
author and date and are listed alphabetically by author in the 40 f 972; Neuhaus and Lynch, 1964) and m~cobacteria (C 
appended bibliography. aceres, 1999; David et al., 1969) are inhibited by 
Mycobacteria cause a number of diseases in humans and D-cycloserine (DCS), a D-alanine analog (Neuhaus, 1967). 
animals including tubevculosis, which is the leading cause of The d i ~ e ~ t i d e  is then added to the UDP-tr i~e~t ide Precursor 
human death from an infectious disease in the world ( ~ l ~ ~ ~  by the action of the D-alanine-D-alanine adding enzyme that 
& Murray, 1992). M. tubevculosis is the principal cause of 45 completes the reactions of the D-alanine branch of pepti- 
tubevculosis in humans and other primates and is occasion- dOgl~can (Walsh, 1989). 
ally seen in dogs, pigs and cattle (O'Reilly & Daborn, 1995). DCS is particularly effective against mycobacteria albeit 
In contrast, M, bovis, the etiologic agent of bovine with marked side effects (Cummings et al., 1955; Yew et al., 
tubevculosis, has a wide host range and infects ruminants, 1993). Moreover, overproduction of Air in MYcobactevium 
carnivores, and primates, including humans (Pritchard, so smegmatis, MYcobactevium intvacellulave, and MYcobacte- 
1988). For M. bovis and M. tubevculosis in both humans and vium bovis BCG leads to a DCS-resistant phenotype. The&'. 
animals, contaminated aerosols are the most common routes smegmatis enzyme is inhibited by DCS in a ~~ncentrat ion-  
of transmission (Carleton, 1993). Other mycobacterial dependent manner ( ~ a c e r e s  et al., 1997). Likewise, the M. 
pathogens of importance are M. avium, M. pavatubevculosis, avium and M. tubevculosis enzymes produced from E. coli 
and M. lepvae. M. avium is the agent of tubevculosis in birds ss recombinant clones are also inhibited by DOS (Strych et al., 
but its major significance is as an opportunistic pathogen of 2001). Nonetheless, the specific characteristics of the myco- 
AIDS patients (Inderlied et al., 1993). M. pavatubevculosis bacterial enzymes involved in peptidoglycan biosynthesis, 
is the etiologic agent of Johne's disease, a granulomatous including the essentiality of each of their functions, remain 
enteritis in ruminants and it has also been linked to a unknown. Such knowledge would be important to the design 
potential etiology of a type of inflammatory bowel disease 60 of specific inhibitors that would serve as novel bactericidal 
(Crohn's disease) in humans (Cocito et al., 1994; Harris and agents to treat M. tubevculosis and M. avium infections. 
Barletta, 2001). Finally, M. lepvae infects humans and Furthermore, the inactivation of the genes encoding for 
armadillos. Though leprosy in humans has low mortality, its these enzymes may lead to the generation of attenuated 
morbidity is quite high in affected areas, estimated to have strains of pathogenic mycobacteria that could serve as 
been 1&12 million in the 1980s (Noordeen, 1991). All these 6s candidate vaccines against tubevculosis. 
diseases caused by mycobacteria are characterized patho- M. smegmatis has been extensively used as a model 
logically by the formation of granulomatous nodules (tumor- system for M. tubevculosis and other mycobacteria. M. 
US 6,929,799 B2 
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smegmatis is nonpathogenic, requiring less stringent con- The present invention employs the following definitions. 
tainment facilities, and it grows at a relatively high rate in a "alrA" and "alr" refer to the D-alanine racemase gene, 
variety of defined and nutrient-restricted media (Jacobs, including normal alleles of the alrA gene. 
2000). M. smegmatis has been used to study drug resistance 
"AlrA" and "Alr" refer to D-alanine racemase enzyme. 
mechanisms (ciceres et al.9 1997; Peteroy et al.9 2000; i'Displays increased susceptibility to antimycobacterial 
Telenti et al.9 1997) and basic ~h~s io log ica l  processes refers to a reduction in the minimal inhibitory con- 
the peptidog1ycan precursors (Ciril10 centration of the mutant strain when with the wild 
et al., 1998; Pavelka and Jacobs, 1996). Insights gained from type strain, 
these studies can then be applied to the pathogenic myco- 
lo "Displays increased susceptibility to bactericidal action of bacteria. phagocytic cells" refers to a reduction in the ability of the 
A - .  
SUMMARY OF THE INVENTION mutant strain to survive and/or replicate in phagocytic cells 
when comvared to the wild tvve strain. 
a. 
It is an object of the present invention to provide a A "promoter" is a DNA sequence that directs the tran- 
D-alanine racemase mutant mycobacteria which can be used scription of a structural gene. Typically, a promoter is 
in development of treatments for diseases caused by patho- located in the 5' region of a gene, proximal to the transcrip- 
genic mycobacteria. tional start site of a structural gene. If a promoter is an 
Accordingly, in one aspect of the present invention, a inducible promoter, then the rate of transcription increases in 
novel mycobacterial strain, comprising a D-alanine race- response to an inducing agent. For example, a promoter may 
mase mutant which is not dependent on D-&nine for 20 be regulated in a tissue-specific manner such that it is only 
growth, designated alrA mutant, is provided. The mycobac- active in transcribing the associated coding region in a 
terial strain is generated from a pathogenic mycobacteviurn. specific tissue type(s). 
Any pathogenic mycobacteria may be used in accordance In contrast, the rate of transcription is not generally 
with the present invention. Preferred pathogenic mycobac- regulated by an inducing agent if the promoter is a consti- 
teria are M. tubevculosis, M. bovis, and all subspecies of M. 25 tutive promoter. The promoter may be tissue-geneal, also 
avium. known as non-tissue-preferred, such that it is active in 
In another aspect of the invention, a live-attenuated vat- transcribing the associated coding region in a variety of 
cine against pathogenic mycobacteria is provided which different tissue types. 
includes the alrA mutant, with or without additional muta- It has been discovered that the M. smegmatis alrA gene 
tions. In one embodiment of this aspect, the alrA mutant 30 can be insertionally inactivated to generate AlrA null 
displays increased susceptibility to an antimycobacterial mutants. Unexpectedly, the inactivation of the alrA gene in 
agent. In a second embodiment, the alrA mutant displays M. smegmatis mutant did not result in a growth requirement 
increased susceptibility to bacterial action of phagocytic for D-alanine. Given the conservation of basic processes 
cells. In a third embodiment, the mutant is a D-alanine within the genus Mycobactevium, a similar outcome cane be 
dependent pathogenic mycobacteviurn. 35 expected in all mycobacterial species. PCR and Southern 
In a further aspect of the present invention, methods for blotting analyses of w i l d - t ~ ~ e  and mutant strains confirmed 
producing live-attenuated vaccines including the alrA the inactivation of the alrA gene in TAM20 and TAM23 by 
mutant are provided. gene replacement via a double-crossover event between the 
M. smegmatis chromosome and the linear fragment carrying In another aspect of the invention, a method for screening 
40 the inactivated gene. Thus, alrA mutants are viable and can 
antimycobacterial agents that are synergistic with pepti- grow in medium without D-alanine. Complementation of the doglycan inhibitors is provided. 
alrA mutant strain with a wild-type alrA copy restores the 
In yet a further aspect of the invention, a method wild-type phenotype, indicating that properties of the mutant 
new pathways D-alanine biOs~nthesis is pro- strain are due to the inactivation of the alrAgene rather than 
vided. The pathways identified may be used 45 a polar effect on the expression of a downstream gene. The 
new drugs that target peptidog1ycan biOs~nthesis in myc0- independence of M, smegmatis alrA mutants of D-alanine 
bacteria and to identify new vaccines useful against patho- for growth indicates that this mutation does not impose an 
genic mycobacteria. auxotrophic requirement for D-alanine. This phenotype has 
DETAILED DESCRIPTION OF THE 
INVENTION 
significant impkcations for the synthesis of D-alanine and 
so peptidoglycan in M. smegmatis and for other mycobacterial 
species. 
The present invention is directed to D-alanine racemase D-Alanine is an essential component for bacteria with a 
mutants of mycobacterial species. The D-alanine racemase peptidoglycan layer structure. The essentiality of D-alanine 
gene (alrA) is involved in the synthesis of D-alanine, a basic stems from the key role of the dipeptide D-alanyl-D-alanine 
component of peptidoglycan that forms the backbone of the ss in the cross-linking of peptidoglycan strands (Strominger, 
bacterial cell wall. The present invention is also directed to 1962). The repeating unit of the peptidoglycan from M. 
methods of making live-attenuated vaccines against patho- smegmatis has a D-alanine moiety (Petit et al., 1969), and 
genic mycobacteria using such alrA mutants and to the D-alanyl-D-alanine is the only product detected in a bio- 
vaccines made according to such methods. The present chemical assay using partially purified extracts of M. smeg- 
invention is further directed to use of alrA mutants in 60 matis D-alanine ligase (Peteroy et al., 2000). These proper- 
methods for screening antimycobacterial agents that are ties support the hypothesis that D-alanine is also an essential 
synergistic with peptidoglycan inhibitors. Finally, the component for M. smegmatis . In the context of this 
present invention is directed to methods to identify new hypothesis, the independence of alrA mutants of D-alanine 
pathways of D-alanine biosynthesis for use in developing for growth suggests that M. smegmatis may have alternative 
new drugs targeting peptidoglycan biosynthesis in myco- 65 pathways for the biosynthesis of D-alanine. Listeria 
bacteria and to identify vaccines useful against pathogenic monocytogenes, for example, has been shown to possess 
mycobacteria. such metabolic routes (Thompson et al., 1998). 
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As described in further detail herein, alrA mutant myco- 
bacteria can be used to develop safe live-attenuated vaccines TABLE 1-continued 
of pathogenic mycobacteria, screen for drugs that act syn- 
ergistically with peptidoglycan inhibitors, and identify new Strains and plasmids 
pathways of D-alanine biosynthesis. In summary, the s strain or Source or 
D-alanine independent phenotype of M. smegmatis alrA plasmid Relevant characteristics reference 
mutants suggests that M. smegmatis has another pathway of 
D-alanine biosynthesis, Given the conservation of basic  matis is Air-KanR, M. smegmatis mutant This 
derived from mcZISS 
physiological processes, this finding is of significance for M, ,egmatis A ~ ~ - K ~ ~ R ,  M, smegmatis mutant n i s  study 
pathogenic mycobacteria and the design of novel attenuated 10 TAM23 derived from mcZ1S5 
strains and antimycobacterial agents. M. smegmatis Alr+HygRKanR, M. smegmatis alr mutant This study 
TAM23 complemented with wild type gene 
Method of Use: Development of Novel alrA Mutant (pTAMU3) integrated at the mycobacteriophage LS 
Mycobacterial Strains attB site 
Novel alrA mutant pathogenic mycobacterial strains can pBUNs2 KanR , recombinant plasmid carrying the (5) 
alr gene from M. smegmatis mcZISS in a be generated in accordance with the present invention. The 1.9 kb BamHIIPvuII fragment 
generation of alrA mutants has been illustrated by prepara- pBluescript AmpR, standard E. coli cloning vector Stratagene 
tion of M. smegmatis alrAmutants. However, other methods " KS + 
known in the art may be used to generate stable alrAmutants pTAMU1 AmpR, pBluescript I1 KS + with This study the 1.9 kb BamHIIPvuII fragment of 
such as chemical mutagenesis followed by mutant pBUN82 in the BamHIIEcoRV site 
enrichment, transposon mutagenesis, plasmid or phage 20 pTAMU2 AmpR KanR, pTAMUl with the This study 
vectors, and methods to produce unmarked in-frame dele- 1.24 kb P S ~ I  aph fragment of pUC4K 
tions. The same procedures described herein may be used to (Pharmacia, Inc. Piscataway, N. J.) in the PstI site 
inactivate the alrA gene of other pathogenic mycobacterial pTAMU3 AmpRHygR, pYUB412 with the This study 
species in order to generate alrA mutants of such species. 1.9 kb BamHIIPvuII fragment of pBUN82 
Such species of mycobacteria include Mycobacteviurn 2s in the BC~IIECORV site 
tubevculosis, Mycobactevium avium, Mycobactevium bovis, pYUB412 AmpRHygR, E. coli-Mycobacterium (33) 
mtegratlon-proficient vector. Integrates 
Mycobacteviurn afvicanum, and Mycobactevium pavatubev- at the mycobacteriophage LS attB site 
culosis To inactivate the alrA gene in M. smegmatis, a DNA 
fragment carrying the wild-type gene was subcloned into the 
E. coli cloning vector pBlue-script I1 KS(+) to yield the 
recombinant plasmid pTAMUl (Table 1). Then, the 1.2-kb 
kanamycin resistance determinant from plasmid pUC4K 
containing the aminoglycoside 3'-phos-photransferase type 
I-coding gene from transposon Tn903 (30) was inserted at 
the unique PstI site internal to the alrA gene. The resulting 
construct, pTAMU2, carries an insertionally inactivated alrA 
gene, which can be excised as a linear 3.2-kb BamHI-kvnl 
fragment (Table 1). Based on the hypotheses that D-alanine 
is an essential component and that AlrA is the only enzyme 
responsible for D-alanine biosynthesis in M. smegmatis, it 
was predicted that an alrA mutant would be dependent on 
D-alanine for growth. Unexpectedly, the inactivation of the 
alrAgene in M. smegmatis mutant did not result in a growth 
requirement for D-alanine. The step to select for this mutant 
was carried out in MADC agar supplemented with 50 mM 
D-alanine in addition to 20 ug of kanamycin per ml. Trans- 
formation of M. smegmatis mc2155 with the 3.2-kb linear 
fragment carrying the inactivated alrA gene yielded 25 
kanamycin-resistant transformants, and 2 of these, desig- 
nated TAM20 and TAM23, were further analyzed. 
To determine whether these transformants carry an inac- 
tivated alrA gene, genomic DNA was isolated and amplified 
by PCR. As expected for the inactivation of the alrA gene, 
genomic DNA from both TAM20 and TAM23 yielded the 
2.4-kb product. Southern blotting analysis was used to verify 
the occurrence of these recombinational events in the appro- 
priate M. smegmatis strains. Genomic DNA was isolated; 
digested with SmaI, which cuts once within the alrA gene; 
transferred to a membrane; and hybridized with the wild- 
type alrA gene fragment as a probe. The wild-type strain 
mc2155 gave two homologous bands of approximately 15.0 
and 1.8 kb, whereas TAM20 and TAM23 yielded a mutant- 
type pattern with three bands of approximately 15.0,2.2, and 
1.2 kb. These patterns were as expected for the predicted 
recombinational events, validating the construction of the 
strains described herein. 
The identification of only one D-alanine racemase gene in 
the mycobacterial genome sequencing projects suggests that 
M. smegmatis alrAmutants may be dependent on exogenous 
D-alanine for growth. Both mutant strains, TAM20 and 
TAM23, exhibited wild-type growth in MADC agar supple- 
mented with D-alanine, giving rise to typical flat-border 
TABLE 1 colonies after 3 days of incubation at 37~: in  the absence of D-alanine, TAM20 and TAM23 cells were also able to grow, 
Strains and plasmids but colonies displayed a drier appearance with more raised 
ss borders. Complementation of TAM23 with the integrating 
Strain or Or construct pTAMU3 introduces a wild-type alrA gene at the 
plasmid Relevant characteristics reference 
mycobacteriophage L5 attachment site (Lee and Hatfull, 
E. coli DHSa F-lacZDM1S endAl hsdRl7 supE44 Invitrogen 1993; Pascopella, 1994) and fully restores wild-type colony 
gyrA96 relAl Life morphology. Except for these differences in colony 
Tech- 
nologies 60 morphology, no other observable differences were detected 
E. coli D(rncrA)183 D ( r n c r C B - h S d ~ ~ ~ - r n r r ) l 7 3  Stratagene by light Or electron microscopy when cells were grown in 
XL2-Blue MRF' endAl supE44 thi-1 recAl gyrA96 the presence or absence of D-alanine. Bacilli from both 
relAl lac [F' proAB lacIqZDM1S wild-type and mutant strains were weakly gram positive, 
TnlO TetR CamR] 
M. smegmatis Alrf, high efficiency plasmid acid fast, and displayed the same aspect of elongated rods. 
mcZ1Ss transformation mutant of M. smegmatis 
(37) 65 Likewise, at the ultrastructural level, cells did not differ in 
mcZ6 either shape, size, or thickness of the cell walls. In summary, 
M. smegmatis alrA mutants are independent of exogenous 
D-alanine, a property that was further confirmed by their 
ability to grow in MADC, as described more frilly herein, 
and minimal broth containing mineral salts, glycerol, pyri- 
doxal phosphate, and Tween 80. 
To determine whether M. smegmatis alrA mutants are or s 
are not devoid of Alr activity, crude cell extracts from 
wild-type and mutant strains were prepared and assayed for 
enzyme activity. Protein extracts prepared from wild type 
mc2155 cells grown in the presence or absence of D-alanine 
displayed approximately equal levels of Air activity that 10 
matched the specific activities previously reported ( ~ a c e r e s  
et al., 1997). In contrast, extracts from TAM23 prepared 
from cells grown in the presence or absence of D-alanine 
lacked any detectable Alr activity. These extracts yielded 
background levels of Alr activity not significantly different IS 
from the levels obtained by replacing bovine serum albumin 
for TAM23 extracts in the reaction mixture. This absence of 
Alr activity in TAM23 extracts was not clue to the presence 
of an inhibitor since mixtures of TAM23 and mc2155 
extracts gave the Air activity proportional to the amount of 20 
enzyme present in the active extract from the wild-type 
strain. Furthermore. to rule out the aossibilitv that sonic 
disruption may have damaged more readily protein extracts 
of potentially fragile TAM23 cells, LDH activity was also 
measured. The M. smegmatis LDH activity was found to be 25 
more sensitive to prolonged sonic disruption and provides a 
useful control to determine whether TAM23 extracts are 
enzymatically active. In contrast to the results obtained in 
the Alr assay, extracts from both mc2155 and TAM23 
displayed similar levels of LDH activity above background 30 
levels. Furthermore, complementation of TAM23 with a 
wild-type air gene restored Alr activity. Thus, it was con- 
cluded that inactivation of the alrA gene results in no 
detectable Alr activity in the M. smegmatis alrA mutant 
strain. 35 
Method of Use: Generation of Live-Attenuated Vaccines 
An ideal vaccine against diseases caused by mycobacteria 
such as tubevculosis, leprosy, and Crohn's disease in humans 
and Johne's disease in dairy cattle should be able to protect 
against the widest possible range of pathogenic bacterial 40 
isolates eliciting a strong CMI requiring presentation of both 
peptide and non-peptide antigens, long-lasting immunologi- 
cal memory, and possibly humoral immunity. Given this 
complexity, live attenuated vaccines may offer the best 
possibilities for an ideal antimycobacterial vaccine. 45 
Furthermore, this type of vaccine could potentially be 
administered orally as enteric-coated lyophilized tablets, 
thus avoiding the use of needles (Barletta et al., 1990). 
Additionally, a live attenuated vaccine could even be made 
compatible with current or experimental new diagnostics SO 
(Cirillo et al., 1995). Although recent studies with subunit 
vaccines have been promising, so far these vaccines con- 
ferred shorter survival than BCG when tested in M. tubev- 
culosis aerogenically challenged guinea pigs, underlying the 
problems to be solved with these types of vaccines (Baldwin 55 
et al., 1998). However, subunit vaccines also may be impor- 
tant for disease control in immunodeficient individuals or in 
areas where the standard skin test has diagnostic signifi- 
cance. Furthermore, a subunit vaccine may be useful to 
boost individuals previously vaccinated with BCG or those 60 
at risk of disease reactivation (Baldwin et al., 1998). 
The generation of a new live-attenuated vaccine poses 
many research challenges. Genetic systems to manipulate M. 
bovis BCG and M. tubevculosis offer the greatest promise for 
the development of new and effective vaccines against 65 
mycobacterial infections. Methods for allelic replacement 
and transposon mutagenesis in slow-growing mycobacteria 
have been reviewed (Pelicic et al., 1998). Using condition- 
ally replicating genetic elements, two groups have reported 
major breakthroughs in the genetic manipulation of M. 
tubevculosis (Bardarov et al., 1997; Pelicic et al., 1997). 
Methods to generate unmarked deletion mutations in M. 
smegmatis, BCG, and M. tubevculosis have been described 
(Pavelka &Jacobs, 1999). This technology coupled with the 
knowledge of the M. tubevculosis genetic blueprint (Cole et 
al., 1998) should provide novel strategies for the rational 
development of live attenuated vaccines. The most promis- 
ing approach for vaccine development would be to start with 
virulent M. tubevculosis microorganisms and generate 
attenuated mutants. These mutants should carrv at least two 
attenuating deletion mutations and no antibiotic resistant 
markers, so as to avoid unwanted reversions or transfers of 
drug-resistance. It is contemplated that vaccine strains gen- 
erated by the method of the present invention will include 
one or more additional mutations. Other imaortant issues to 
consider are a) the degree of attenuation: mutants that are too 
attenuated may not induce protective immunity as it was the 
case for S. typhimuvium phoP mutants (Fields et al., 1989); 
and b) whether the effect of the vaccine strain could be 
potentiated by co-administration of cytokines or by endow- 
ing the engineered strain with the capability to produce 
cytokines or phagosome membrane disrupters as lysteriol- 
ysin. In this case, temporal expression of these genes may be 
critical and may have to be regulated by promoters solely 
active inside phagocytic cells, as for example the promoter 
of the mig gene, first identified in M. avium (Plum & 
Clark-Curtiss, 1994) with a corresponding homologue 
(fadD19) found in the M. tubevculosis genome sequence 
(Cole et al., 1998). 
Candidate genes for attenuating mutations may be those 
directly involved in the pathogenic process or those encod- 
ing housekeeping enzymes whose suppression may alter the 
ability of M. tubevculosis to survive and/or replicate within 
phagocytes. The best documented examples of mutations 
leading to attenuated phenotypes in vivo are the inactiva- 
tions or deletions of the M. tubevculosis genes erp (Berthet 
et al., 1998), hma (Dubnau et al., 2000), katG (Li et al., 
1998), leuD (Hondalus et al., 2000), mgtC (Buchmeier et al., 
2000), and the recently described cyclopropane synthetase 
gene pcaA (umaA2) involved in cord formation (Glickman 
et al., 2000), and purC (Jackson et al., 1999). In addition, a 
M. tubevculosis deletion mutant unable to synthesize myco- 
bactin was generated and shown to be impaired for growth 
in a human macrophage cell line (De Voss et al., 2000). 
Additional candidate genes and previous work has been 
summarized elsewhere (Cole et al., 1998). Other candidates 
are unidentified mycobacterial genes such as those involved 
in the inhibition of phagosome acidification (Sturgill- 
Koszycki et al., 1994; Via et al., 1998). It may be also 
possible to identify and inactivate genes responsible for 
subtle changes in the structure of lipoarabinomannan since 
these changes influence receptor-mediated uptake and ulti- 
mately intracellular fate and overall virulence (Kang & 
Schlesinger, 1998). Another approach that has been fol- 
lowed for the attenuation of M. tubevculosis is to engineer a 
recombinant strain overexpressing a global negative regu- 
lator of virulence genes. In this context, it was found that a 
recombinant M. tubevculosis carrying a dominant constitu- 
tively active iron repressor was attenuated in mice (Manabe 
et al. 1999). The above literature also describes standard 
methods for testing candidate vaccine strains in animal 
model systems such as mice or guinea pigs. 
It was discovered that M. smegmatis alrAmutants display 
an increased susceptibility to bactericidal action of phago- 
cytic cells such as macrophages (Chacon, O., 2002, incor- 
porated herein by reference.) Based on this finding, patho- 
genic species of mycobacteria having an inactivated alrA 
gene could be constructed using methods known in the art. 
Such strains would be useful for the generation of attenuated s 
live-attenuated vaccine candidates against tubevculosis and 
other human or animal diseases caused by mycobacteria 
such as leprosy and Crohn's disease and Johne's disease. 
Further, based on the discovery that alrA mutants are 
impaired in the ability to synthesize the basic building block 10 
of cell walls, peptidoglycan, vaccine strains which undergo 
spontaneous lysis in vivo can be constructed using methods 
known in the art. Lysis would allow for improved antigen 
delivery and containment of the vaccine strain. 
To determine the effect of the inactivation of the alrAgene IS 
on the intracellular survival of M. smegmatis in phagocytic 
cells, monolayers of human macrophages were infected with 
wild type, mutant and recombinant control strains. Prior to 
infection, M. smegmatis strains were grown in medium 
supplemented with D-alanine which results in approxi- 20 
mately the same rate of growth for all strains. Growth in 
monolayers was carried out in absence of D-alanine to 
approximate the conditions expected in the host. Monolay- 
ers were infected with M. smegmatis strains at a multiplicity 
of approximately 10 bacilli per cell, invasion was allowed to 25 
proceed for 2 h and extracellular bacteria were removed. At 
24, 48 and 72 h post-infection, the number of intracellular 
surviving bacteria was determined as described in Materials 
and Methods. As expected, the wild type strain mc2155 
displayed moderate survival in monolayers of adherent 30 
human macrophages, with about 5-fold reduction in the 
number of intracellular bacteria after 72 h of incubation of 
the monolavers. In contrast. the alrA mutant strain TAM23 
was less able to survive reaching a 5-fold reduction in 
intracellular bacilli at 24 h and 500-fold by 72 h. Thus, the 35 
inactivation of the alrA gene has a significant effect on the 
ability of M. smegmatis to survive within phagocytic cells. 
To verifv that the decreased survival of the mutant strain 
was due to the inactivation of the alrA gene, M. smegmatis 
TAM23 was complemented with a wild type copy which 40 
was delivered into the chromosome using an integrating 
vector. Strain TAM23(pTAMU3), carrying both the inacti- 
vated and wild type copies of the alrA gene, displayed wild 
type survival in human macrophages. This result confirmed 
that the inactivation of the alrA gene is responsible for the 45 
reduced survival of TAM23. In addition, the effects of 
introducing selection markers on the survival of M. smeg- 
matis in phagocytic cells were tested using appropriate 
recombinant control strains. The kanamycin-resistant 
marker used to inactivate the alrA gene was introduced into so 
the chromosome of the wild type strain via an integrating 
vector. The resulting recombinant strain mc2155(pYUB178) 
displayed the same survival pattern as the wild type strain 
indicating that the introduction of this marker does not affect 
the intracellular survival of M. smegmatis. Since the vector ss 
used to complement the mutant strain carries a hygromycin- 
resistant marker, strain TAM23 was also transformed with 
this vector alone to generate the recombinant alrA mutant 
strain TAM23(pYUB412). In this case, the survival of this 
recombinant strain was slightly affected by the introduction 60 
of this marker. At 24 h post-infection, both TAM23 and 
TAM23(pYUB412) displayed a 5-fold reduction in intrac- 
ellular survival; however at 48 and 72 h post-infection, 
TAM23(pYUB412) displayed an intermediate level of sur- 
vival when compared to the wild type and TAM23 mutant 65 
strains. (FIG. 4). Thus, the hygromycin resistant marker has 
an influence on intracellular survival at longer times post- 
infection. Nonetheless, the effect is minor and significantly 
different from the complete recovery of the survival of 
TAM23 conferred, at every time-point post-infection, by the 
hygromycin-resistant integrating vector pTAMU3 carrying 
the wild type gene. 
Method of Use: Identification of New Antimycobacterial 
Agents 
In  addition to new effective vaccines against a 
mycobacteria, there is also an urgent need to develop new 
antimycobacterial agents. These new agents should be effec- 
tive against these microorganisms without being toxic to the 
mammalian host. Drug therapy is the major approach to treat 
human mycobacterioses. Several primary and secondary 
anti-mycobacterial agents are currently used to treat human 
tubevculosis. The Food and Drug Administration has 
approved the following drugs as primary agents: 
ethambutol, isoniazid, pyrazynamide, rifampin, and strep- 
tomycin. Examples of approved second-line drugs are: 
amikacin, ciprofloxacine, cycloserine, ethionamide, and 
para-aminosalicylic acid. Recommended treatments use 
combination therapies with three agents for at least six 
months. However, these regimens are becoming ineffective 
due to the emergence of drug resistance strains, including 
the appearance of clinical isolates with multiple resistances 
to various primary and secondary drugs (Edlin et al., 1992; 
Kochi et al., 1993; Musser & Barry 1998). Thus, there is an 
urgent need to develop new and more effective anti- 
tubevculosis drugs. 
u 
Recent studies on mycobacterial drug resistance have 
focused on the study of specific biochemical targets of the 
primary and secondary drugs (Musser et al., 1999). For a 
summary of the principal targets identified to date, see 
Chacon, Ph.D. Thesis 2002, incorporated herein in its 
entirety. In all these cases, the common theme is that these 
targets are enzymatic proteins involved in key metabolic 
processes for the Mycobacteviurn. Identification and bio- 
chemical analysis of these proteins is then applied to the 
rational design of new and more effective anti-mycobacterial 
agents (Zhang & Telenti, 2000). Furthermore, genes encod- 
ing for some of these proteins may also serve as targets for 
the generation of attenuated strains that could be useful in 
developing effective vaccines against mycobacteria. This 
might be the case with genes playing an important role in 
metabolic pathways that are necessary for the biosynthesis 
of mycobacterial structural components. One of these genes, 
involved in the biosynthesis of peptidoglycan, is the alrA 
gene. The present invention is equally applicable to other 
mycobacterial genes involved in the synthesis of D-alanine. 
The inhibition of AlrA by DCS in a concentration- 
dependent manner indicates that this enzyme serves as one 
of the drug targets (Caceres et al, 1997). However, the 
dispensability of the alrA gene for growth in vitro suggests 
that it is not the main target responsible for the bactericidal 
effect of DCS. Since overproduction of the enzyme leads to 
increased resistance to DCS, it appears that binding of DCS 
to AlrA protects another target within the cell. This hypoth- 
esis predicts that AlrA null mutants would be hypersuscep- 
tible to DCS. Thus, the corresponding MICs for wild-type 
and TAM23 alrA mutant strains were determined. 
For MIC tests, M. smegmatis cells grown with and 
without n-alanine were inoculated onto complete Middle- 
brook MADC broth without D-alanine. The MIC of DCS for 
the wild-type strain was 75 pglml, independent of the 
presence of D-alanine in the original inoculum (Table 2). As 
expected, TAM23 was about 30-fold more sensitive (MIC, 
2.56 pglml) when the inoculum was grown without 
D-alanine. Since TAM23 cells carry a mutation in a gene 
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responsible for D-alanine biosynthesis, it is possible that However, it must be emphasized that considering absolute 
growth in the presence of D-alanine partially restores wild- drug concentrations, the effect on the mutant strain is 
type MICs of DCS. To test this hypothesis, TAM23 was observed at a 30-fold-lower concentration than for the 
grown with D-alanine, harvested, washed extensively to wild-type strain. This pattern suggests that the bactericidal 
prevent D-alanine carryover, and inoculated into the MIC 5 ,,tion of DCS is due to the inhibition of a more fundamental 
test cultures. These conditions resulted in a fourfold increase target different from d r ~ ,  
in the MIC (MIC, 10.2), still about 7.5 times lower than the An alternative explanation for the increased susceptibility 
MIC for the w i l d - t ~ ~ e  strain. As a control, the MICs of the of the null mutants to DCS is that the inactivation of the alrA 
unrelated drugs amikacin, ethambutol, and rifabutin were gene changes the permeability of the cell wall to DCS, m i s  
also determined. The MICs for both w i l d - t ~ ~ e  and mutant 10 alteration may not be detectable by morphological studies. 
strains were the same, independently of the Presence or To test this hypothesis, a methodology to perform DCS 
absence of D-alanine in the medium used to grow the uptake assays was developed. The results obtained were 
inocula to determine the MICs. The effect of the addition of similar for both wild-type and mutant strains, ~ - ~ l ~ ~ i ~ ~  
D-alanine directly into the MIC test cultures was also uptake assays using a standardized procedure obtaining 
determined. D-Alanine would be expected to effectively IS similar results for both strains was also carried out. Thus, a 
compete with DCS and decrease the susceptibilities of both permeability change was ruled out as responsible for the 
strains to DCS. As expected, under these conditions, the observed phenotype of the null mutants, 
MIC of DCS for both w i l d - t ~ ~ e  and TAM23 strains The uptakes of D-alanine and DCS in both wild-type and 
increased dramatically to 1,200~glml independently of prior mutant strains were not significantly different, indicating 
growth conditions of the inocula. No significant differences 20 that changes in cell wall permeability are not a likely 
were observed for the other unrelated drugs, demonstrating explanation for the DCS increased susceptible phenotype of 
that the effect was specific for DCS. Complementation of the alrA mutant strain. Thus, the increased susceptibility of 
strain TAM23 with the integrating vector pTAMU3, which T - 2 3  cells to DCS is consistent with the existence of 
carries the wild-type air gene, resulted in a strain for which multiple targets for DCS, our previous studies identified 
the MICs were identical to those for the wild type. 25 D-alanine racemase as one of these targets (Caceres et al, 
1997). The lack of the racemase protein in the alrA mutant 
TABLE 2 strain may lead to a hypersusceptible phenotype since more 
DCS would be required to inhibit both the racemase and an 
Minimal inhibitory concentrations of M. smegmatis wild type and 
TAM23 alr mutant strains to selected antimycobacterial agents additional target(s) in the wild-type strain. In contrast, the 
determined with inocula grown with or without D-alanine. 30 bactericidal effect of DCS suggests the existence of another 
lethal target. In this context, D-alanine ligase is an attractive 
Minimal Inhibitorv Concentrationa (MIC, ~ g l m l )  candidate since this enzyme activity is also inhibited by 
Wild Tvpe mcZ 155 TAM23 alr Mutant DCS (David, 1969; Chacon, Ph.D. thesis). More 
importantly, the construction of a conditionally lethal mutant 
Without With Without With 35 bank led to the isolation of a thermosensitive mutant 
Drug D-alanineb D-alaninec D-alanineb D-alaninec impaired in this gene function et al,, 2000). 
Amikacin 1.56 N.D. 1.56 1.56 Furthermore, increased DCS susceptibility may reflect an 
D-Cvcloserine 75.0 75.0 2.56 10.2 alteration of the vevtidonlvcan structure of TAM23 cells. as 
. . u ,  
~thahbuto l  3.13 N.D. 3.13 3.13 a direct consequence of the inactivation of the alr gene. In 
Rifabutin 2.00 N.D. 2.00 40 this context, TAM23 cells were also more susceptible to 
aMICs were determined in complete Middlebrook 7H9 medium as DCS than were wild-type cells when grown in medium with 
described in Materials and Methods. For a given drug, MIC differences of D-alanine, but mutant cells grown without D-alanine dis- 
- 
the two strains are considered significant when values correspond to a played increased susceptible to both growth inhibition and 
separation of at least two doubling dilutions. 
b~noculum was grown in complete Middlebrook 7H9 medium without the bactericidal action of DCS. 
D-alanine supplementation, as described in Materials and Methods. 45 Based on the finding that inactivation of the alrA gene of 
CInoculum was grown in complete Middlebrook 7H9 medium supple- M. smegmatis yielded a strain with increased susceptibility 
mented with 50 mM D-alanine, as described in Materials and Methods. to D-alanine analogs, the generation of Alr null mutants as 
This increased susceptibility indicated by the MIC growth vaccine candidates would be possible using methods known 
inhibition data was also confirmed by the analysis of the in the art. The present invention accordingly seeks to pro- 
bactericidal action of DCS in broth cultures grown in SO vide novel live-attenuated mycobacteria as vaccines. Such 
absence of D-alanine. Pilot experiments were performed vaccines would be especially effective for treatment of 
with each strain to determine the optimal DCS concentration immunosuppressed patients, or others displaying signs of 
that resulted in a strong bactericidal effect. In the final disease, with drugs such as D-alanine analogs. 
experiment, cultures were grown to an early exponential Method of Use: Use of D-Alanine Racemase Mutants to 
phase (OD,,, of -0.4), split in two, and DCS was added to ss Identify New Pathways of D-Alanine Biosynthesis 
one of these subcultures at 50 times the MIC. In absence of It was discovered that M. smegmatis D-alanine racemase 
DCS, both the wild-type strain mc2155 and the TAM23 mutants can synthesize D-alanine by verifying the presence 
mutant cells grew to a OD,,, of >2.0 and reached saturation of D-alanine within the internal amino acid pool of TAM23. 
at a cell density approximately above 5 .0~10 .  These data To determine the gene(s) responsible for the alternative 
also confirmed the independence of M smegmatis air 60 pathway of D-alanine biosynthesis, the following procedure 
mutants on D-alanine for growth and further demonstrate is followed: 1) a transposon mutant bank of TAM23 is 
that air mutants can grow in absence of D-alanine at approxi- constructed, 2) mutants are screened for the ability to grow 
mately the same growth rate as wild-type cells. In contrast, in the presence or absence of D-alanine in the growth 
in the presence of DCS both cells underwent rapid death by medium, 3) mutants unable to grow in the absence of 
lysis as revealed by both the drastic decrease observed in 65 D-alanine are identified by replica, 4) the region containing 
optical density and viable counts. Furthermore, the kinetic of the transposon is cloned, and 5) the gene inactivated by the 
killing was similar for both the wild-type and mutant strains. transposon is identified by DNA sequencing. Alternatively, 
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a proteomic analysis of TAM23 can be performed before and 1.0~10-5 mM manganese chloride, 16 mM monobasic 
after a shift from medium with D-alanine to media without potassium phosphate ,  4 . 9 ~ 1 0 - 6  mM pyr idoxa l  
D-alanine. Proteins induced under the latter conditions are hydrochloride, 0.4 mM Tween 80, and 8.6~10-6 mM zinc 
candidates for enzymes involved in an alternative pathway sulfate. Individual chemicals were purchased from Sigma. 
of D-alanine biosynthesis. Protein spots are sequenced, and s 
~ ~ ~ t ~ ~ i ~ l  transformation, E, coli was transformed as pre- 
the coding are identified and then inactivated to viously described (Ausubel et al., 1990). For the generation 
construct strains carrying multiple mutations. These strains 
. f ~ ,  smegmatis alr~mutants ,  50 of an early exponential 
are evaluated for their dependency on D-alanine for growth. phase culture of M, smegmatis mc2155 was washed twice 
Based on the finding thatTAM23 mutant of M. smegmatis and concentrated 100-fold in cold 10% ultrapure glycerol 
was independent of D-alanine for growth, the inactivation of 10  it^^^^^   if^ ~ ~ ~ h ~ ~ l ~ ~ i ~ ~ ,  carisbad, calif,), concen- 
the gene provides a means to study alternate metabolic trated cells were electroporated with approximately 5.0pg of 
pathways related to ~ e ~ t i d o g l ~ c a n  synthesis in pathogenic the BamHI-KpnI fragment of pTAMU2 carrying the inac- 
m~cobacteria. The discovery that m~cobacteria Possess a tivated alrA gene. Electroporation was carried out at 2,500 
novel pathway of ~ e ~ t i d o g l ~ c a n  synthesis, makes possible V. 100 pF, and 246 Q in an electrocell manipulator (model 
the exploitation, using methods known in the art, of such in 1s 600; BTX Inc., San Diego, Calif.). Electroporated cells were 
the generation of other attenuated strains and new antimy- allowed to recover at 3 7 ~  in MADC broth and plated on 
cobacterial drugs. The present invention accordingly seeks MADC agar supplemented with 50 m~ ~ - ~ l ~ ~ i ~ ~  (sigma) 
to provide novel AlrA null mutant mycobacterial strains for and kanamycin (20 pglml; sigma), F~~ the genetic cornpie- 
use in determining alternate metabolic pathways of mentation experiment, 50 ml of an early-exponential phase 
D-alanine andlor peptidoglycan biosynthesis in the identi- 20 culture  of^, smegmatis T - 2 3  a l r ~ m u t a n t  was electropo- 
fication of drug targets for development of new bactericidal rated with 1.5 mg of p ~ ~ ~ 3  DNA at 2,500 V, 25 p ~ ,  and 
agents for the treatment of mycobacterial diseases. 1,000 Q in a Gene Pulser electrocell manipulator (Bio-Rad 
Method of Use: Use of a DCS H ~ ~ e r - S u s c e ~ t i b l e  Mutant to Laboratories, Richmond, Calif.), as previously described 
Screen for Cell Wall Inhibitors (Foley et al., 1995). Transformants were selected on MADC 
An alrA mutant can be used to screen for inhibitors of 25 agar supplemented with hygromycin (100 pglml; ~ ~ ~ h ~ ) ,  
peptidoglycan synthesis following methods known in the art Nucleic acid manipulations, Mycobacterial DNA was (KamOgashira and Takegata, 1988, herein isolated by the standard method using cetyl trimethyl ammo- 
reference). nium bromide (Ausubel, 1990). Plasmid DNA was isolated 
EXAMPLES by an alkaline lysis method as previously described 
30 (Sambrook, 1989), using a large-scale isolation kit 
The present invention is further described in the following (promega, ~ ~ d i ~ ~ ~ ,  wis,) as recommended by the manu- 
examples, which are offered by way of illustration and are facturer. DNAfragments used for plasmid construction in E. 
not intended to limit the invention in any manner. Standard coli and for recombination experiments in M, smegmatis 
techniques well known in the art or the techniques described were purified by gel e~ectrop~oresis and recovered by 
below are utilized in the practice of the present invention. 35 absorption to glass particles ( G ~ ~ ~ c ~ ~ ~ ~  ~i  101, vista, 
Calif.) as recommended by the manufacturer. Standard pro- Example 1 
cedures were followed for restriction digestions, ligations, 
Generation of M. smegmatis alrA Mutants and agarose gel electrophoreses (Sambrook, 1989). 
Bacterial strains, plasmids, and culture conditions. Bac- 
terial strains and plasmids used in this study are listed in 
Table 1. E. coli strains were grown at 37C in Luria-Bertani 
broth or agar. M. smegmatis strains were routinely grown at 
37C in Middlebrook 7H9 base broth or agar (BBL Micro- 
biology Systems, Cockeysville, Md.) supplemented with 
0.5% bovine serum albumin fraction V (EM Science, 
Gibbstown, N.J.), 0.01 M dextrose (Sigma Chemical Co., St. 
Louis, Mo.), 0.015 M sodium chloride, and 0.2% glycerol 
(MADC). Broth medium was also supplemented with 0.05% 
Tween go (Sigma), and solid medium was made with 1.5% 
Bacto Agar (Difco Laboratories, Detroit, Mich.). When 
required, 0-alanine (Sigma) was used at 50 mM. Liquid 
cultures were incubated with shaking at 200 rpm in an 
Innova 4300 rotary incubator (New Brunswick Scientific 
Co. Inc., Edison, N.J.). As needed, the following antibiotics 
were used at the specified concentrations: ampicillin 
(Sigma), 50 pglml for E. coli; kanamycin A monosulfate 
(Sigma), 25 pglml for E. coli and 20 pgiml for M. smeg- 
matis; hygromycin B (Roche Molecular Biochemicals, 
Indianapolis, Ind.), 100 pglml for E. coli and M. smegmatis. 
For some experiments, M. smegmatis was grown in a broth 
minimal medium based on the formulation of Zygmunt, 
1963, as modified by Caceres, 1999. Components and final 
concentrations were 5.0 mM ammonium chloride, 6 .8~10-7 
mM calcium chloride, 8 .4~10-7 mM cobalt(I1) chloride, 22 
mM dibasic potassium phosphate, 2.5~10-10 mM ferric 
chloride, 21 mM glycerol, 2.4 mM magnesium sulfate, 
Amplification of the alrAgene was carried out with 50 ng 
of M. smegmatis genomic DNA template using primers 
NAN-1 and NAN-2 for 27 cycles in a thermal cycler 
(Perkin-Elmer Gene Amp PCR System 2400; Roche 
Molecular Systems, Branchhurg, N.J.) as previously 
described (Caceres, 1997). For Southern blotting analysis, 
approximately 3.0 pg of M. smegmatis genomic DNA was 
digested with SmaI, and DNA fragments were separated on 
a 0.8% agarose gel, subjected to an alkaline denaturing 
procedure, and transferred to Biotrans nylon membranes 
(ICN Biomedicals, Inc., Costa Mesa, Calif.). Membranes 
were hybridized with a probe corresponding to the 1.9-kb 
BamHI/PvuII fragment containing the wild-type M. smeg- 
matis alr gene, which was radiolabeled with [a-32PldCTP 
using the Rediprime DNA labeling I1 system (Amersham 
Pharmacia Biotech, Inc., Piscataway, N.J.) as recommended 
by the manufacturer. Prehybridization and hybridization 
were performed at 56C. Washes were done under high- 
stringency conditions at 65C as previously described 
(Sambrook, 1989). 
Gram staining and acid-alcohol resistance testing. M. 
smegmatis cells were stained by the crystal violet method 
using a Gram stain kit (Sigma) as recommended by the 
manufacturer. Acid-alcohol resistance was determined by 
the Zielsi-Neelsen acid-fast procedure using the TB Stain 
Kit ZN (Difco), as recommended by the manufacturer. 
Electron microscopy. Strains were grown to an optical 
density at 600 nm (OD655) of approximately 1.0 in MADC- 
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Tween, with or without D-alanine. Cells were harvested, tions. M. srnegrnatis mc2155 and TAM23 cells were grown 
washed twice with phosphate-buffered saline (PBS)-0.05% in 25 ml of MADC-Tween with and without 50 mM 
Tween, and fixed for 1 h in 2.5% buffered glutaraldehyde, D-alanine to an OD,,, of approximately 1.0. Bacteria were 
washed twice, and postfixed with 2.0% osmium tetroxide. washed with pBS-Tween, and 105 CFU was inoculated onto 
After repeated washings in PBS, samples were dehydrated s each well containing serial twofold dilutions of various 
in a graded series of ethanol solutions, washed twice in antimicrobial agents, plates were incubated at 3 7 ~ ,  and 
propylene and embedded with Araldite resin. 'Ihin visual inspection to determine MICs was carried out at 48 h. 
sections were examined with a Philips 201 transmission The MIC is defined as the lowest concentration that prevents Optics, EindhOvetn observable bacterial growth and is determined by the con- The at an of 60 kV' 10 sistent result of three independent cultures, each assayed in 
D-Alanine racemase assays. Approximately 200-ml cul- triplicate, 
tures of M. srnegrnatis mc2155 or TAM23 were grown in 
MADC-Tween with or without D-alanine until they reached M. srnegrnatis strains mc2155 and TAM23 were grown in 
an OD,,, of ca. 1.0. Cultures were washed twice and MADC-Tween at 37C an OD,,, ca. 0.5. These 
concentrated 50-fold in 50 m~ T ~ ~ ~ - H c ~  ( p  8.0). cells starter cultures were used to inoculate 200 ml of MADC 
were sonicated on a salt-ice-water bath with a Vibra-Cell broth, and cells were then grown to an OD600 of ca. 0.4. Two 
model VC600 sonicator (Sonic and Materials, Inc., Danbury, 50-ml aliquots of these exponentially growing cultures were 
Conn.). Sonication was carried out for 2 min at 80% power transferred to separate flasks. DCS was added to one of the 
output and 50% duty cycle, and in the presence of 30% corresponding cultures, with the other serving as a growth 
(vol/vol) type A-5 alumina (Sigma). The resulting active cell control. Concentrations of DCS were 50 times the MIC for 
extracts were centrifuged at 4C in a JA-17 rotor (Beckman 20 each strain (3.75 mglml for mc2155 and 128 pglml for 
Instruments, Inc., Fullerton, Calif.) for 30 mm at 15,000 TAM23). All cultures were incubated at 37C in a shaking 
rPm, dialyzed against 50 mM Tris-HCl(pH 8.0), and steril- incubator for 72 h. The OD,,, was measured for each culture 
ized by filtration through a 0.22-~-~oresize filter (Advantec at 3, 6, 9, 12, 24, 48, and 72 h. Concurrently, aliquots were 
MFS Inc., Pleasanton, Calif.). Protein concentration was taken, serially diluted, and plated onto M ~ C  agar in 
determined the DC assay (BiO-Rad) as 25 triplicate to determine numbers of viable bacterial counts. 
the manufacturer. Alr activity in the active cell extracts was 
assayed in the direction of the conversion of L-alanine into Example 4 
D-a lan ine  by  a modif icat ion of the coupled-  
spectrophotometric method previously described (Caceres, D-Alanine Uptake Assays 
1999). To start the reactions, active crude cell extracts were 30 F~~ ~ - ~ l ~ ~ i ~ ~  uptake assays, the method described by 
added to 1.0 ml of prewarmed mixtures containing 50 mM David, 1971, was used, Cells exponentially growing in 
Tris-HC1 (pH 8.0), mM pyridoxal phosphate (Sigma), MADC-Tween (OD,,,, ca, 1.0) were collected by 
and 15 mM L-alanine (Sigma). After 15 min of incubation gation at 40C, washed once in ice-cold 50 mM Tris-HC1 
at 37C, when the conversion of substrate into product 
remains linear, reactions were stopped by boiling for 10 min. buffer (pH 8.0) containing 0.05% Tween 80, and concen- 
Subsequently, of d-amino acid oxidase (Calzyme, Sari 35 trated 20 times in the same buffer. Samples were prewarmed 
Lois Obispo, Calif.), 0.2 mM NADH (Roche Laboratories), for lo at 37C3 and D-alanine was added to a 
and 10 U of rabbit muscle lactic dehydrogenase (Sigma) 3.0 pCi [14Cl-1-D-a1anine (ICN) per 
were added. The coupled reaction was measured by the iumol asid 0.2 mM ~~ncentration. Samples were placed in a 
change in absorbance at 340 nm after 5 h of incubation at 37C water bath. Aliquots were taken at various times and 
37C. All samples were measured in triplicate. Specific 40 immediately placed on ice. The sample for each time ~ o i n t  
activities (in micromoles of consumed substrate minute-1 was divided in three subsample triplicates of 0.5 ml and 
milligram-1) were calculated as previously described filtered through 0.8-pm-pore-size membrane filters 
(Caceres et al, 1997). (Millipore Corp., Bedford, Mass.) in a manifold. Each filter 
LDH assays. L-Lactate dehydrogenase (LDH) activity was washed three times with 10 ml of cold buffer, dried 
endogenous to crude cell extracts of M. srnegrnatis was 45 under a heat lamp, and weighed. The cell-associated radio- 
measured in the direction of the conversion of pyruvate into activity was determined in a liquid scintillation counter 
lactate coupled to the oxidation of NADH as previously (Wallac 1410; Pharmacia, Piscataway, N.J.) using EcoLite 
described in the Worthington enzyme n~anual (Worthington scintillation cocktail (ICN). Uptake data were expressed as 
Biochemical Gorp., Lakewood, N.J.1. crude cell extracts micromoles of D-alanine per milligram (dry cell weight). 
were added to m1 of prewarmed mixtures containing 50 50 Since radiolabeled DCS is not commercially available, an 
mM Tris-HC1 (pH 8.0), mM pymvate (Sigma), uptake assay was developed based on the colorimetric 
and 0'2 mM NADH (Roche)' The change in absorbance at determination of this compound (Jones, 1956). Cells expo- 
340 nm was measured after 1 h of incubation at 37C. All 
samples were measured in triplicate, Specific activities (in "entially growing in (OD6O0 of -'") were 
micromoles of consumed substrate minute-l milligram-l) harvested at 4C washed twice with water, 
were calculated as described in the enzyme manual men- ss and concentrated 40 times. Samples were prewarmed at 37C 
tioned above by subtracting the background change in for 10 min, and DCS was added to a final concentration of 
absorbance (obtained from boiled inactivated extracts pro- 250 MIm1 (-2.5 mM). were placed in a 37C water 
cessed in identical manner) from the change in absorbance bath. Aliquots were taken at various times and immediately 
obtained with the active cell extracts. placed on ice. After 20 min of incubation, clumping of 
60 TAM23 cells was evident and uptake determinations became Example 2 
unreliable. Each time a point sample was washed twice with 
Generation of M. tubevculosis alrA Mutants water, resuspended, and sonicated. Protein concentration 
Example 3 was determined using the Bio-Rad DC assay, followed by 
protein removal through serial passages of both YM-10 and 
Drug Susceptibility Assays 65 YM-3 Centricon concentrators (Millipore Corp.). The con- 
MICs were determined by a microplate twofold dilution centration of DCS was determined by measuring the OD620 
method, as described by Takiff et al., 1996, with modifica- after adding a specific color-developing reagent as previ- 
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ously described (Jones, 1956). A standard curve was gener- Recombinant BCG as a candidate oral vaccine. Res. Micro- 
ated by diluting a DCS standard in a cell extract that was biol. 141, 931-939. 
prepared from cells not exposed to DCS. Uptake data were Belanger, A. E., and J. M. Inamine. 2000. Genetics of cell 
expressed as micromoles of DCS per milligram of protein. wall biosynthesis, p. 191-202. In G. F. Hatfull and W. R. 
Since D-alanine and DCS uptake assays do not measure the s Jacobs, Jr. (ed.), Molecular genetics of mycobacteria. ASM 
same parameters, reported values for each assay cannot be Press, Washington, D.C. 
directly compared. Belanger, A. E., J. C. Porter, and G. F. Hatfull. 2000. 
Genetic analysis of peptidoglycan biosynthesis in mycobac- 
Example 5 teria: characterization of a ddlA mutant of Mycobactevium 
lo smegmatis. J. Bacteriol. 182:6854-6856. 
Increased Susceptibility to Phagocytic Cells Bermudez, L. E. & Yound, L. S. (1988). Tumor necrosis 
Intracellular killing assays were carried out as described factor, alone or combination with IL-2, but not IFN-gamma, 
previously with the following modifications (Bermudez and is with macrophage of 
Young, 1988). Approximately 5x10' monocytes were lmmunol l4O9  3006-3013' 
seeded on each well of a 24-well tissue culture plate 1s Berthet, F. X., Lagranderie, M., Gounon, P., C., L. W., 
(Sigma). Plates were incubated for 2 h at 37 C in 5% CO,. Ensergueix, D., Chavarot, P., Thouron, F., Maranghi, E., 
Supernatant fluids with nonadherent cells were removed and Pelicic, V., Portnoi, D., Marchal, G. & Giequel, B. (1998). 
the wells were washed twice with 1.0 ml of prewarmed Attenuation of virulence by disruption of the Mycobacte- 
HBSS. The adherent monocytes were maintained in culture tubevculosis erp gene' Science 2822 759-762' 
for 7 days with 1.5 ml of RPMI 1640 (Gibco) supplemented 20 B1attner, F. R., V. G. P1unkett II1, H. J. and 
with mM L-glutamine (Sigma) and heat-inactivated D. L. Daniels. 1993. Analysis of the Eschevichia coli 
fetal bovine serum (Sigma), Culture media was replaced genome. IV. DNA sequence of the region from 89.2 to 92.8 
every 48 hours. Each well was inoculated with approxi- minutes. Acids 21:5408-5417. 
mately 5.0x106 CFU of bacteria. After 2 h, macrophage B. R. & C. J. L. Tubevculosis: 
monolayers were washed three times with HBSS to remove 25 O n  a reemergent Science 2573 
extracellular microorganisms. Some wells were lysed imme- 1055-1064. 
diately with 0.5 ml of sterile water for 10 min and 0.025% Braustein M., Bardarov S, Jacobs W R Jr. 2002. Genetic 
SDS (Sigma) in HBSS for additional 10 SDS was methods for deciphering virulence determinants of Myco- 
subsequently inactivated with 0.1% bovine albumin bacterium tubevculosis. Meth Enzymol. 358:67-99. 
(Sigma). The lysate was serially diluted and plated onto 30 Buchmeier, N., Blanc-Potard,A., Ehrt, S., Piddington, D., 
Middlebrook 7H9 based agar (BBL) supplemented with Riley, L. & Groisman, E. A. (2000). A parallel intraphago- 
0.5% fraction V albumin (EM Science), 0.01 M dextrose soma1 survival strategy shared by mycobactevium tubevcu- 
(Sigma), 0.015 M sodium chloride (Sigma), 0.15% glycerol losis and Salmonella entevica. Mol. Microbiol. 35, 
(Sigma) and 1.5% Bacto agar (Difco). The same procedure 1375-1382. 
was done on two other sets of wells at 24, 48 and 72 hours. 35 ciceres, N. E., N. B. Harris, J. F. Wellehan, Z. Feng, V. 
I l ~ r e e  wells were carried out Per experimental group, in each Kapur, and R. G. Barletta. 1997. Overexpression of the 
of three independent experiments. It is to be noted that a D-alanine racemase gene confers  resistance to 
preliminary experiment using 20 ~ g l m l  of amikacin during D-cycloserine in Mycobactevium smegmatis. J. Bacteriol. 
the invasion step to kill extracellular bacteria yielded similar 179:5046-5055. 
results, demonstrating the effectiveness of the washing pro- 40 ciCeres, N, E, 1999, p h , ~ ,  thesis, university o f~ebraska ,  
cedure. Lincoln. 
While the invention has been disclosed in this patent Carleton, p, (1993). Respiratory tubevculosis, In Pathol- 
application by reference to the details of preferred embodi- ogy of  ti^ h i m a i s ,  pp, 493-502, ~ d i t ~ d  by K, V, F, 
ments of the invention, it is to be understood that the jubb, p, C, ~~~~~d~ & N, palmer, orlando, ~ l ~ , :  ~ ~ d ~ ~ i ~  
disclosure is intended in an illustrative rather than in a 45 press I,,, 
limiting sense, as it is contemplated that modifications will chacon, 0, ~ ~ ~ l ~ ~ i ~ ~  and characterization of ~ ~ ~ ~ b ~ ~ ~ ~ -  
readily occur to those skilled in the art, within the spirit of 
,ium smegmatis ~ - ~ ~ ~ l i ~ ~  racemase mutants, p h , ~ ,  ~ h ~ ~ i ~ ,  
the invention and the scope of the appended claims. Texas A&M University. December 2002. 
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What is claimed and desired to be secured by Letters 6. The recombinant mycobacteria of claim 1, wherein said 
Patent is as follows: recombinant mycobacteria further comprises one or more 
1. A recombinant rnycobacteviurn comprising an inacti- additional mutations, whereby said recombinant mycobac- 
vated alrAgene, wherein said rnycobacteviurn is independent teria is rendered dependent on D-alanine for growth. 
of D-alanine for growth. s 7. The recombinant mycobacteria of claim 1, wherein said 
2. The recombinant rnycobacteviurn of claim 1, wherein recombinant mycobacteria displays increased susceptibility 
said rnycobacteviurn is selected from the group consisting of to bactericidal action of phagocytic cells. 
Mycobacteviurn srnegrnatis, and subspecies thereof. 8. The recombinant mycobacteria of claim 1, wherein said 
3. The recombinant mycobacteria of claim 1, wherein said recombinant mycobacteria further comprises a single 
recombinant mycobacteria further comprises one or more 10 D-alanine ligase gene under the control of an inducible 
additional mutation encoding peptide or non-peptide anti- promoter, said promoter controlling the expression of 
gens from a pathogenic mycobacteria. D-alanyl-D-alanine. 
4. The recombinant mycobacteria of claim 1, wherein said 9. The recombinant rnycobacteviurn of claim 2, wherein 
recombinant mycobacteria displays increased susceptibility said rnycobacteviurn is a strain designated TAM20. 
to an antimycobacterial agent. IS 10. The recombinant rnycobacteviurn of claim 2, wherein 
5. The recombinant mycobacteria of claim 4, wherein said said rnycobacteviurn is a strain designated TAM23. 
antimycobacterial agent is selected from the group consist- 
ing of D-cycloserine and other D-alanine analogs. * * * * *  
